<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038829</url>
  </required_header>
  <id_info>
    <org_study_id>SUN101-201</org_study_id>
    <nct_id>NCT02038829</nct_id>
  </id_info>
  <brief_title>A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD</brief_title>
  <acronym>GOLDEN 6</acronym>
  <official_title>A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD: GOLDEN 6 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion Respiratory Development Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion Respiratory Development Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium
      bromide 400 mcg 2x a day will be given as an active comparator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, six-way crossover study to determine the efficacy and dose-response
      profile of SUN101. The study population will consist of subjects 40 to 65 years-old
      (inclusive), with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg bid will
      be given as an active comparator. The study will be double-blind for SUN-101 and placebo and
      will be open-label for aclidinium.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo.</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the 2 spirometry values collected at 23 hours 15 minutes, and 23 hours 45 minutes post-morning dose on Day 7 of each Treatment Period. The FEV1 values within 6 hours after the use of rescue medication were considered as missing. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standardized Change From Baseline in FEV1 AUC(0-12hours)</measure>
    <time_frame>Day 7</time_frame>
    <description>The standardized FEV1 AUC(0-12) on Day 7 was calculated using the trapezoidal rule from the changes in FEV1 from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment)</measure>
    <time_frame>Over 7 days</time_frame>
    <description>A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment)</measure>
    <time_frame>Over 7 days</time_frame>
    <description>A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUN-101 3 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUN-101 3 mcg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUN-101 6.25 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUN-101 6.25 mcg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUN-101 12.5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUN-101 12.5 mcg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SUN-101 50 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SUN-101 50 mcg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aclidinium 400 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aclidinium 400 mcg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUN101 3 mcg</intervention_name>
    <description>SUN-101 3 mcg bid</description>
    <arm_group_label>SUN-101 3 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUN-101 6.25 mcg</intervention_name>
    <description>SUN-101 6.25 mcg bid</description>
    <arm_group_label>SUN-101 6.25 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUN-101 12.5 mcg</intervention_name>
    <description>SUN-101 12.5 mcg bid</description>
    <arm_group_label>SUN-101 12.5 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SUN-101 50 mcg</intervention_name>
    <description>SUN-101 50 mcg bid</description>
    <arm_group_label>SUN-101 50 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aclidinium</intervention_name>
    <description>Aclidinium 400 mcg bid</description>
    <arm_group_label>Aclidinium 400 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients 40 to 65 years-old, inclusive.

          2. A clinical diagnosis of moderate to severe COPD according to the GOLD 2011 guidelines.

          3. Current smokers or ex-smokers with at least 10 pack year smoking history (eg, at least
             1 pack/day for 10 years, or equivalent).

          4. Post bronchodilator (following inhalation of ipratropium bromide) FEV1 ≥ 40% and ≤ 70%
             of predicted normal during Screening.

          5. Post bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio ≤
             0.70 during Screening.

          6. Post bronchodilator (following inhalation of ipratropium bromide) improvement in FEV1
             ≥ 12% and ≥ 100 mL during Screening.

          7. Ability to perform reproducible spirometry according to the American Thoracic Society
             (ATS) and European Respiratory Society (ERS) guidelines (2005).

          8. Female of child bearing potential (only) must have a negative serum pregnancy test at
             Screening and be neither breastfeeding nor intending to become pregnant during study
             participation. Females of childbearing potential must be instructed to and agree to
             avoid pregnancy during the study. Female subjects of child bearing potential must use
             an adequate method of birth control from Screening until 30 days after receiving study
             drug and use contraception in addition to their partners using a barrier method.
             Acceptable forms of contraception are as follows:

               -  Abstinence

               -  Barrier methods: condoms, diaphragms, cervical caps; with a spermicide foam, gel,
                  film, cream or suppository;

               -  Oral contraceptives

               -  Non hormone containing intrauterine methods: intrauterine devices or systems.

          9. Willing and able to remain at the study site for at least 24 hours at Day 7 of each
             Treatment Period.

         10. Willing and able to attend all study visits and adhere to all study
             assessments/procedures.

         11. Willing and able to provide written informed consent

        Exclusion Criteria:

          1. Current evidence or recent history of any clinically significant and unstable disease
             (other than COPD) or abnormality in the opinion of the Investigator that would put the
             subject at risk or which would compromise the quality of the study data; including but
             not limited to cardiovascular disease, myocardial infarction, cardiac failure,
             uncontrolled hypertension, life threatening arrhythmias, uncontrolled diabetes,
             neurologic or neuromuscular disease, liver disease, gastrointestinal disease or
             electrolyte abnormalities.

          2. Current evidence or history of a clinically significant abnormality of cardiac rhythm
             and/or conduction including Holter monitoring prior to randomization.

          3. Primary diagnosis of asthma.

          4. History of malignancy of any organ system, treated or untreated within the past 5
             years, with the exception of localized basal cell carcinoma of the skin.

          5. Recent history of COPD exacerbation requiring hospitalization or need for increased
             treatments for COPD within 6 weeks prior to Screening.

          6. Use of daily oxygen therapy &gt; 10 hours per day.

          7. Use of systemic steroids within 3 months prior to Screening.

          8. Respiratory tract infection within 6 weeks prior to or during Screening.

          9. History of tuberculosis, bronchiectasis or other non-specific pulmonary disease.

         10. History of urinary retention or bladder neck obstruction type symptoms.

         11. History of narrow angle glaucoma.

         12. Prolonged QTcF interval (males &gt; 450 msec and females &gt;470 msec) during Screening, or
             history of long QT syndrome.

         13. Recent history (previous 12 months) of excessive use or abuse of alcohol or
             narcotic/illegal drugs.

         14. History of hypersensitivity or intolerance to aerosol medications, beta-2 agonists, or
             anticholinergics.

         15. Participation in another investigational drug study where drug was received within 30
             days prior to Screening, or current participation in another investigational drug
             trial.

         16. Subject is a staff member of the clinical site or a relative of a clinical site staff
             member.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SUN101 Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sunovion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research, Inc.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Carolina Clinical Research</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute of Southern Oregon, PC</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Medical Research Associates, LLC</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Pharmaceutical Research, Inc.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Pharmaceutical Research</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S. Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CU Pharmaceutical Research</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Donohue JF, Goodin T, Tosiello R, Wheeler A. Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies. Respir Res. 2017 Dec 4;18(1):202. doi: 10.1186/s12931-017-0681-z.</citation>
    <PMID>29202767</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2014</study_first_posted>
  <results_first_submitted>January 2, 2018</results_first_submitted>
  <results_first_submitted_qc>January 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2018</results_first_posted>
  <disposition_first_submitted>August 25, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 25, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 7, 2015</disposition_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Eligible subjects will be randomized to one of 12 treatment sequences. There will be a minimum of a 7-day washout period between each treatment visit. At each visit, subjects will receive one dose of study medication according to the sequence assigned.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group 1</title>
          <description>Participants received SUN-101 50mcg; Aclidinium 400mcg; Placebo; SUN-101 6,25mcg; SUN-101 3mcg; SUN-101 12.5mcg</description>
        </group>
        <group group_id="P2">
          <title>Treatment Group 2</title>
          <description>Participants received Placebo; SUN-101 50mcg; SUN-101 3mcg Aclidinium 400mcg; SUN-101 12.5 mcg; SUN-101 6mcg</description>
        </group>
        <group group_id="P3">
          <title>Treatment Group 3</title>
          <description>Participants received SUN-101 3mcg Placebo; SUN-101 12.5 mcg; SUN-101 50mcg; SUN-101 6.25mcg Aclidinium 400mcg;</description>
        </group>
        <group group_id="P4">
          <title>Treatment Group 4</title>
          <description>Participants received SUN-101 12.5 mcg; SUN-101 3mcg Placebo; SUN-101 50mcg; Aclidinium 400mcg; SUN-101 6.25mcg</description>
        </group>
        <group group_id="P5">
          <title>Treatment Group 5</title>
          <description>Participants received SUN-101 6.25mcg SUN-101 12.5 mcg; Aclidinium 400mcg; SUN-101 3mcg SUN-101 50mcg Placebo;
Aclidinium 400mcg; SUN-101 6.25mcg</description>
        </group>
        <group group_id="P6">
          <title>Treatment Group 6</title>
          <description>Participants received Aclidinium 400mcg; SUN-101 6.25mcg SUN-101 50mcg SUN-101 12.5 mcg; Placebo; SUN-101 3mcg
Placebo;</description>
        </group>
        <group group_id="P7">
          <title>Treatment Group 7</title>
          <description>Participants received SUN-101 3mcg SUN-101 50mcg Aclidinium 400mcg; Placebo; SUN-101 6.25mcg SUN-101 12.5 mcg;
SUN-101 3mcg</description>
        </group>
        <group group_id="P8">
          <title>Treatment Group 8</title>
          <description>Participants received Aclidinium 400mcg; SUN-101 3mcg SUN-101 6.25mcg SUN-101 50mcg SUN-101 12.5 mcg; Placebo;</description>
        </group>
        <group group_id="P9">
          <title>Treatment Group 9</title>
          <description>Participants received SUN-101 6.25mcg Aclidinium 400mcg; SUN-101 12.5 mcg SUN-101 3mcg Placebo; SUN-101 50mcg</description>
        </group>
        <group group_id="P10">
          <title>Treatment Group 10</title>
          <description>Participants received SUN-101 12.5 mcg SUN-101 6.25mcg Placebo; Aclidinium 400mcg; SUN-101 50 mcg SUN-101 3mcg</description>
        </group>
        <group group_id="P11">
          <title>Treatment Group 11</title>
          <description>Participants received Placebo; SUN-101 12.5 mcg SUN-101 50 mcg SUN-101 6.25mcg Aclidinium 400mcg; SUN-101 3mcg</description>
        </group>
        <group group_id="P12">
          <title>Treatment Group 12</title>
          <description>Participants received SUN-101 50 mcg Placebo; SUN-101 3mcg SUN-101 6.25mcg Aclidinium 400mcg; SUN-101 12.5 mcg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="8"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 5</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 6</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total</title>
          <description>Total of all participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.6" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo.</title>
        <description>Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the 2 spirometry values collected at 23 hours 15 minutes, and 23 hours 45 minutes post-morning dose on Day 7 of each Treatment Period. The FEV1 values within 6 hours after the use of rescue medication were considered as missing. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period</description>
        <time_frame>Baseline and Day 7</time_frame>
        <population>Efficacy Population: all subjects who were randomized to treatment, received at least one dose of study medication, and had at least one trough FEV1 evaluation and the corresponding baseline FEV1 for at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo bid
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 3 mcg</title>
            <description>SUN-101 3 mcg bid
SUN101 3 mcg: SUN-101 3 mcg bid</description>
          </group>
          <group group_id="O3">
            <title>SUN-101 6.25 mcg</title>
            <description>SUN-101 6.25 mcg bid
SUN-101 6.25 mcg: SUN-101 6.25 mcg bid</description>
          </group>
          <group group_id="O4">
            <title>SUN-101 12.5 mcg</title>
            <description>SUN-101 12.5 mcg bid
SUN-101 12.5 mcg: SUN-101 12.5 mcg bid</description>
          </group>
          <group group_id="O5">
            <title>SUN-101 50 mcg</title>
            <description>SUN-101 50 mcg bid
SUN-101 50 mcg: SUN-101 50 mcg bid</description>
          </group>
          <group group_id="O6">
            <title>Aclidinium 400 mcg</title>
            <description>Aclidinium 400 mcg bid
Aclidinium: Aclidinium 400 mcg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo.</title>
          <description>Spirometry was performed according to internationally accepted standards. Trough FEV1 was defined as the average of the 2 spirometry values collected at 23 hours 15 minutes, and 23 hours 45 minutes post-morning dose on Day 7 of each Treatment Period. The FEV1 values within 6 hours after the use of rescue medication were considered as missing. Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period</description>
          <population>Efficacy Population: all subjects who were randomized to treatment, received at least one dose of study medication, and had at least one trough FEV1 evaluation and the corresponding baseline FEV1 for at least one treatment period.</population>
          <units>liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0282" spread="0.0300"/>
                    <measurement group_id="O2" value="-0.0156" spread="0.0300"/>
                    <measurement group_id="O3" value="0.0540" spread="0.0238"/>
                    <measurement group_id="O4" value="0.0806" spread="0.0300"/>
                    <measurement group_id="O5" value="0.1092" spread="0.0300"/>
                    <measurement group_id="O6" value="0.1285" spread="0.0300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with mean change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 66 subjects (rounding to 72 for using Williams squares and 96 with dropouts) provides ~90% power to detect a 100 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in trough FEV1 of 176 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>0.9730</p_value>
            <p_value_desc>P-values were adjusted using Dunnett’s method for comparing the multiple treatments to placebo. The comparison of aclidinium to placebo was performed at the 0.05 significance level to establish assay sensitivity.</p_value_desc>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.0126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0225</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0318</ci_lower_limit>
            <ci_upper_limit>0.0569</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with mean change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 66 subjects (rounding to 72 for using Williams squares and 96 with dropouts) provides ~90% power to detect a 100 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in trough FEV1 of 176 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>0.0014</p_value>
            <p_value_desc>P-values were adjusted using Dunnett’s method for comparing the multiple treatments to placebo. The comparison of aclidinium to placebo was performed at the 0.05 significance level to establish assay sensitivity.</p_value_desc>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.0822</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0225</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0380</ci_lower_limit>
            <ci_upper_limit>0.1264</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with mean change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 66 subjects (rounding to 72 for using Williams squares and 96 with dropouts) provides ~90% power to detect a 100 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in trough FEV1 of 176 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values were adjusted using Dunnett’s method for comparing the multiple treatments to placebo. The comparison of aclidinium to placebo was performed at the 0.05 significance level to establish assay sensitivity.</p_value_desc>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.1088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0226</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0644</ci_lower_limit>
            <ci_upper_limit>0.1532</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with mean change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 66 subjects (rounding to 72 for using Williams squares and 96 with dropouts) provides ~90% power to detect a 100 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in trough FEV1 of 176 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values were adjusted using Dunnett’s method for comparing the multiple treatments to placebo. The comparison of aclidinium to placebo was performed at the 0.05 significance level to establish assay sensitivity.</p_value_desc>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.1375</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0226</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0931</ci_lower_limit>
            <ci_upper_limit>0.1818</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with mean change from baseline in trough FEV1 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 66 subjects (rounding to 72 for using Williams squares and 96 with dropouts) provides ~90% power to detect a 100 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in trough FEV1 of 176 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-values were adjusted using Dunnett’s method for comparing the multiple treatments to placebo. The comparison of aclidinium to placebo was performed at the 0.05 significance level to establish assay sensitivity.</p_value_desc>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.1567</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0226</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1121</ci_lower_limit>
            <ci_upper_limit>0.2012</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Standardized Change From Baseline in FEV1 AUC(0-12hours)</title>
        <description>The standardized FEV1 AUC(0-12) on Day 7 was calculated using the trapezoidal rule from the changes in FEV1 from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval).</description>
        <time_frame>Day 7</time_frame>
        <population>Efficacy Population: all subjects who were randomized to treatment, received at least one dose of study medication, and had at least one trough FEV1 evaluation and the corresponding baseline FEV1 for at least one treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo bid
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 3 mcg</title>
            <description>SUN-101 3 mcg bid
SUN101 3 mcg: SUN-101 3 mcg bid</description>
          </group>
          <group group_id="O3">
            <title>SUN-101 6.25 mcg</title>
            <description>SUN-101 6.25 mcg bid
SUN-101 6.25 mcg: SUN-101 6.25 mcg bid</description>
          </group>
          <group group_id="O4">
            <title>SUN-101 12.5 mcg</title>
            <description>SUN-101 12.5 mcg bid
SUN-101 12.5 mcg: SUN-101 12.5 mcg bid</description>
          </group>
          <group group_id="O5">
            <title>SUN-101 50 mcg</title>
            <description>SUN-101 50 mcg bid
SUN-101 50 mcg: SUN-101 50 mcg bid</description>
          </group>
          <group group_id="O6">
            <title>Aclidinium 400 mcg</title>
            <description>Aclidinium 400 mcg bid
Aclidinium: Aclidinium 400 mcg bid</description>
          </group>
        </group_list>
        <measure>
          <title>Standardized Change From Baseline in FEV1 AUC(0-12hours)</title>
          <description>The standardized FEV1 AUC(0-12) on Day 7 was calculated using the trapezoidal rule from the changes in FEV1 from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval).</description>
          <population>Efficacy Population: all subjects who were randomized to treatment, received at least one dose of study medication, and had at least one trough FEV1 evaluation and the corresponding baseline FEV1 for at least one treatment period.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0203" spread="0.0315"/>
                    <measurement group_id="O2" value="0.0323" spread="0.0316"/>
                    <measurement group_id="O3" value="0.0639" spread="0.0315"/>
                    <measurement group_id="O4" value="0.1052" spread="0.0316"/>
                    <measurement group_id="O5" value="0.1760" spread="0.0315"/>
                    <measurement group_id="O6" value="0.1699" spread="0.0316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with standardized FEV1 AUC(0-12) on Day 7 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 78 subjects (rounding to 84 for using Williams squares) provides ~80% power to detect a 55 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in AUC(0-12) of 143 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>0.0046</p_value>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.0526</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0184</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0163</ci_lower_limit>
            <ci_upper_limit>0.0888</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with standardized FEV1 AUC(0-12) on Day 7 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 78 subjects (rounding to 84 for using Williams squares) provides ~80% power to detect a 55 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in AUC(0-12) of 143 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.0842</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0185</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0478</ci_lower_limit>
            <ci_upper_limit>0.1206</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with standardized FEV1 AUC(0-12) on Day 7 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 78 subjects (rounding to 84 for using Williams squares) provides ~80% power to detect a 55 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in AUC(0-12) of 143 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.1255</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0186</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0890</ci_lower_limit>
            <ci_upper_limit>0.1621</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with standardized FEV1 AUC(0-12) on Day 7 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 78 subjects (rounding to 84 for using Williams squares) provides ~80% power to detect a 55 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in AUC(0-12) of 143 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.1963</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0184</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1601</ci_lower_limit>
            <ci_upper_limit>0.2325</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>An mixed effects model was used with standardized FEV1 AUC(0-12) on Day 7 as the response, with factors for treatment, period, sequence, baseline FEV1 as a covariate and a random effect for subject nested within sequence. The Kenward and Roger correction to the degrees of freedom was used. An unstructured covariance model was used to model intrasubject correlation.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A sample size of 78 subjects (rounding to 84 for using Williams squares) provides ~80% power to detect a 55 mL treatment difference in mean change trough FEV1 between SUN-101 and placebo at a Bonferroni-adjusted significance level of 0.0125 using a 2-tailed paired t-test and assuming a within-subject standard deviation for change in AUC(0-12) of 143 and a within-subject correlation of 0.3.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>LS Mean (SE)</method>
            <param_type>LS Mean (SE)</param_type>
            <param_value>0.1902</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0186</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1537</ci_lower_limit>
            <ci_upper_limit>0.2268</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment)</title>
        <description>A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.</description>
        <time_frame>Over 7 days</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo bid
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 3 mcg</title>
            <description>SUN-101 3 mcg bid
SUN101 3 mcg: SUN-101 3 mcg bid</description>
          </group>
          <group group_id="O3">
            <title>SUN-101 6.25 mcg</title>
            <description>SUN-101 6.25 mcg bid
SUN-101 6.25 mcg: SUN-101 6.25 mcg bid</description>
          </group>
          <group group_id="O4">
            <title>SUN-101 12.5 mcg</title>
            <description>SUN-101 12.5 mcg bid
SUN-101 12.5 mcg: SUN-101 12.5 mcg bid</description>
          </group>
          <group group_id="O5">
            <title>SUN-101 50 mcg</title>
            <description>SUN-101 50 mcg bid
SUN-101 50 mcg: SUN-101 50 mcg bid</description>
          </group>
          <group group_id="O6">
            <title>Aclidinium 400 mcg</title>
            <description>Aclidinium 400 mcg bid
Aclidinium: Aclidinium 400 mcg bid</description>
          </group>
          <group group_id="O7">
            <title>TOTAL</title>
            <description>Total number of study participants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment)</title>
          <description>A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="94"/>
                <count group_id="O7" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment)</title>
        <description>A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.</description>
        <time_frame>Over 7 days</time_frame>
        <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo bid
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>SUN-101 3 mcg</title>
            <description>SUN-101 3 mcg bid
SUN101 3 mcg: SUN-101 3 mcg bid</description>
          </group>
          <group group_id="O3">
            <title>SUN-101 6.25 mcg</title>
            <description>SUN-101 6.25 mcg bid
SUN-101 6.25 mcg: SUN-101 6.25 mcg bid</description>
          </group>
          <group group_id="O4">
            <title>SUN-101 12.5 mcg</title>
            <description>SUN-101 12.5 mcg bid
SUN-101 12.5 mcg: SUN-101 12.5 mcg bid</description>
          </group>
          <group group_id="O5">
            <title>SUN-101 50 mcg</title>
            <description>SUN-101 50 mcg bid
SUN-101 50 mcg: SUN-101 50 mcg bid</description>
          </group>
          <group group_id="O6">
            <title>Aclidinium 400 mcg</title>
            <description>Aclidinium 400 mcg bid
Aclidinium: Aclidinium 400 mcg bid</description>
          </group>
          <group group_id="O7">
            <title>TOTAL</title>
            <description>Total number of study participants</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment)</title>
          <description>A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.</description>
          <population>Safety population was defined as all subjects who were randomized to treatment and received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="92"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="94"/>
                <count group_id="O7" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="24.2"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="26.7"/>
                    <measurement group_id="O5" value="15.2"/>
                    <measurement group_id="O6" value="25.5"/>
                    <measurement group_id="O7" value="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Over 7 days</time_frame>
      <desc>A treatment emergent serious adverse event (TESAE) is any SAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any SAE with both a missing start and stop date.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo bid
Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>SUN-101 3 mcg</title>
          <description>SUN-101 3 mcg bid
SUN101 3 mcg: SUN-101 3 mcg bid</description>
        </group>
        <group group_id="E3">
          <title>SUN-101 6.25 mcg</title>
          <description>SUN-101 6.25 mcg bid
SUN-101 6.25 mcg: SUN-101 6.25 mcg bid</description>
        </group>
        <group group_id="E4">
          <title>SUN-101 12.5 mcg</title>
          <description>SUN-101 12.5 mcg bid
SUN-101 12.5 mcg: SUN-101 12.5 mcg bid</description>
        </group>
        <group group_id="E5">
          <title>SUN-101 50 mcg</title>
          <description>SUN-101 50 mcg bid
SUN-101 50 mcg: SUN-101 50 mcg bid</description>
        </group>
        <group group_id="E6">
          <title>Aclidinium 400 mcg</title>
          <description>Aclidinium 400 mcg bid
Aclidinium: Aclidinium 400 mcg bid</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>cardia failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>metapneumovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="92"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="92"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="92"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>In the event the Study is part of a multi-center study, the first publication of the results of the Study shall be made in conjunction with the results of other participating study sites as a multi-center publication; provided however, if a multi-center publication is not forthcoming within twenty-four (24) months following completion of the Study at all sites, Institution and Investigator shall be free to publish.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Respiratory Medical Director</name_or_title>
      <organization>Sunovion Pharmaceuticals Inc.</organization>
      <phone>1-866-503-6351</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

